358 related articles for article (PubMed ID: 35933457)
1. Implementation of Chromatic Super CAZ/AVI
Bianco G; Boattini M; Comini S; Leone A; Bondi A; Zaccaria T; Cavallo R; Costa C
Eur J Clin Microbiol Infect Dis; 2022 Sep; 41(9):1165-1171. PubMed ID: 35933457
[TBL] [Abstract][Full Text] [Related]
2. Emergence of ceftazidime/avibactam resistance in carbapenem-resistant Klebsiella pneumoniae in China.
Zhang P; Shi Q; Hu H; Hong B; Wu X; Du X; Akova M; Yu Y
Clin Microbiol Infect; 2020 Jan; 26(1):124.e1-124.e4. PubMed ID: 31494252
[TBL] [Abstract][Full Text] [Related]
3. Impact of Ceftazidime-Avibactam Treatment in the Emergence of Novel KPC Variants in the ST307-Klebsiella pneumoniae High-Risk Clone and Consequences for Their Routine Detection.
Hernández-García M; Castillo-Polo JA; Cordero DG; Pérez-Viso B; García-Castillo M; Saez de la Fuente J; Morosini MI; Cantón R; Ruiz-Garbajosa P
J Clin Microbiol; 2022 Mar; 60(3):e0224521. PubMed ID: 35107303
[TBL] [Abstract][Full Text] [Related]
4. Increased Expression and Amplification of
Li X; Zhang J; Yang C; Li J; Wang J; Huang W; Zeng L; Liang X; Long W; Zhang X
Microbiol Spectr; 2022 Aug; 10(4):e0095522. PubMed ID: 35900090
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of ceftazidime-avibactam in various combinations for the treatment of experimental osteomyelitis due to Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae.
Davido B; Crémieux AC; Vaugier I; Gatin L; Noussair L; Massias L; Laurent F; Saleh-Mghir A
Int J Antimicrob Agents; 2023 Jan; 61(1):106702. PubMed ID: 36476965
[TBL] [Abstract][Full Text] [Related]
6. In vitro activity of ceftazidime/avibactam against Gram-negative strains in Colombia 2014-2018.
Lemos-Luengas EV; Rentería-Valoyes S; Cárdenas-Isaza P; Ramos-Castaneda JA
J Glob Antimicrob Resist; 2022 Jun; 29():141-146. PubMed ID: 35257971
[TBL] [Abstract][Full Text] [Related]
7. In vitro activity of ceftazidime/avibactam against carbapenem-nonsusceptible Klebsiella penumoniae isolates collected during the first wave of the SARS-CoV-2 pandemic: a Southern Italy, multicenter, surveillance study.
La Bella G; Lopizzo T; Lupo L; Angarano R; Curci A; Manti B; La Salandra G; Mosca A; De Nittis R; Arena F
J Glob Antimicrob Resist; 2022 Dec; 31():236-238. PubMed ID: 36208851
[TBL] [Abstract][Full Text] [Related]
8. Successive Emergence of Ceftazidime-Avibactam Resistance through Distinct Genomic Adaptations in
Giddins MJ; Macesic N; Annavajhala MK; Stump S; Khan S; McConville TH; Mehta M; Gomez-Simmonds A; Uhlemann AC
Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29263067
[TBL] [Abstract][Full Text] [Related]
9. Acquisition of a Stable and Transferable
Huang J; Zhang S; Zhao Z; Chen M; Cao Y; Li B
Front Cell Infect Microbiol; 2021; 11():658070. PubMed ID: 34354959
[TBL] [Abstract][Full Text] [Related]
10. In vitro activity of ceftazidime-avibactam against Gram-negative strains in Chile 2015-2021.
Torres-Castillo LC; Fandiño C; Ramos MP; Ramos-Castaneda JA; Rioseco ML; Juliet C
J Glob Antimicrob Resist; 2023 Dec; 35():143-148. PubMed ID: 37714380
[TBL] [Abstract][Full Text] [Related]
11. OXA-48-Mediated Ceftazidime-Avibactam Resistance Is Associated with Evolutionary Trade-Offs.
Fröhlich C; Sørum V; Thomassen AM; Johnsen PJ; Leiros HS; Samuelsen Ø
mSphere; 2019 Mar; 4(2):. PubMed ID: 30918055
[TBL] [Abstract][Full Text] [Related]
12.
Stone G; Wise M; Utt E
Microbiol Spectr; 2024 Mar; 12(3):e0147323. PubMed ID: 38329363
[TBL] [Abstract][Full Text] [Related]
13. Acquisition of resistance to ceftazidime-avibactam during infection treatment in
García P; Brito B; Alcalde-Rico M; Munita JM; Martínez JRW; Olivares-Pacheco J; Quiroz V; Wozniak A
Front Cell Infect Microbiol; 2022; 12():981792. PubMed ID: 36118031
[TBL] [Abstract][Full Text] [Related]
14. Resistance to ceftazidime-avibactam in a KPC-2-producing Klebsiella pneumoniae caused by the extended-spectrum beta-lactamase VEB-25.
Findlay J; Poirel L; Bouvier M; Gaia V; Nordmann P
Eur J Clin Microbiol Infect Dis; 2023 May; 42(5):639-644. PubMed ID: 36877262
[TBL] [Abstract][Full Text] [Related]
15. Ceftazidime-Avibactam resistance in clinical isolates of carbapenem-resistant Klebsiella pneumoniae: A phenotypic and genotypic analysis.
Krithika VM; Ganesan V; Rajendran T
Indian J Med Microbiol; 2024; 49():100603. PubMed ID: 38705276
[TBL] [Abstract][Full Text] [Related]
16. Antimicrobial Activity of Ceftazidime-Avibactam and Comparators against Pathogens Harboring OXA-48 and AmpC Alone or in Combination with Other β-Lactamases Collected from Phase 3 Clinical Trials and an International Surveillance Program.
Lin LY; Debabov D; Chang W; Stone G; Riccobene T
Antimicrob Agents Chemother; 2022 Mar; 66(3):e0198521. PubMed ID: 35225651
[No Abstract] [Full Text] [Related]
17. Colonization by ceftazidime/avibactam-resistant KPC-producing Klebsiella pneumoniae following therapy in critically ill patients.
Gaibani P; Bovo F; Bussini L; Bartoletti M; Lazzarotto T; Viale P; Pea F; Ambretti S
Clin Microbiol Infect; 2023 May; 29(5):654.e1-654.e4. PubMed ID: 36716999
[TBL] [Abstract][Full Text] [Related]
18. Update of clinical application in ceftazidime-avibactam for multidrug-resistant Gram-negative bacteria infections.
Zhen S; Wang H; Feng S
Infection; 2022 Dec; 50(6):1409-1423. PubMed ID: 35781869
[TBL] [Abstract][Full Text] [Related]
19. In vitro interaction of ceftazidime-avibactam in combination with different antimicrobials against KPC-producing Klebsiella pneumoniae clinical isolates.
Gaibani P; Lewis RE; Volpe SL; Giannella M; Campoli C; Landini MP; Viale P; Re MC; Ambretti S
Int J Infect Dis; 2017 Dec; 65():1-3. PubMed ID: 28951106
[TBL] [Abstract][Full Text] [Related]
20.
Barnes MD; Winkler ML; Taracila MA; Page MG; Desarbre E; Kreiswirth BN; Shields RK; Nguyen MH; Clancy C; Spellberg B; Papp-Wallace KM; Bonomo RA
mBio; 2017 Oct; 8(5):. PubMed ID: 29089425
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
